文献速递免疫规划慢病防控与筛查卫生政策与健康促进

英格兰基层医疗中慢性肝病成人甲型肝炎疫苗接种覆盖率:一项回顾性队列研究

Hepatitis A vaccination coverage in adults with chronic liver disease in primary care in England: a retrospective cohort study.
PubMed 文献 · Lancet Public Health · 2025-01-01

该回顾性队列研究利用英格兰牛津-皇家全科医师学院研究与监测中心(RSC)基层医疗哨点网络数据,纳入2012年1月1日至2022年12月31日确诊慢性肝病的625079名成人,分析甲型肝炎疫苗接种覆盖率及死亡情况。结果显示仅2.2%接种首剂、0.4%完成两剂,接种率随年龄、社会经济状态、城乡及诊断类型存在差异,作者认为接种率低且存在不平等,应采取措施减少差异。

要点

  • 慢性肝病成人甲肝疫苗首剂覆盖率仅2.2%,完成两剂者仅0.4%。
  • 接种者死亡率5.3%,未接种者死亡率16.5%。
  • 接种可能性在年轻、非吸烟、城市居住、高社会经济状态及MASLD患者中更高。

核心结论

  • 英格兰慢性肝病成人甲型肝炎疫苗接种率低,且随年龄、城乡和社会经济状态存在差异。
  • 作者认为应采取步骤减少疫苗接种中的不平等。

研究设计与样本

  • 回顾性队列研究,使用牛津-皇家全科医师学院研究与监测中心(RSC)基层医疗哨点网络常规收集的医疗记录数据。
  • 纳入2012年1月1日至2022年12月31日确诊慢性肝病、年龄18岁及以上者,共625079人纳入分析。
  • 采用多状态生存模型估计慢性肝病诊断、首剂甲肝疫苗接种、第二剂接种和死亡四种状态间的转移概率。

主要发现

  • 625079名慢性肝病患者中,13875人(2.2%)接种首剂甲肝疫苗,3007人(0.4%)接种第二剂。
  • 13875名接种者中732人(5.3%)死亡,611204名未接种者中101065人(16.5%)死亡。
  • 调整死亡竞争风险后,年轻年龄五分位组接种可能性更高(HR 5.46,95%CI 5.13-5.81),非吸烟者HR 1.59(95%CI 1.54-1.65),城市居民HR 1.28(95%CI 1.21-1.35),较高社会经济状态者HR 1.06(95%CI 1.03-1.10),MASLD患者HR 1.71(95%CI 1.64-1.78)。
  • 有害饮酒史者接种可能性更低(HR 0.36,95%CI 0.32-0.39),1型糖尿病者HR 0.46(95%CI 0.36-0.57),慢性肾病者HR 0.63(95%CI 0.57-0.70),精神障碍者HR 0.66(95%CI 0.64-0.69)。
  • 死亡风险最低见于感染性或自身免疫性病因的慢性肝病患者以及MASLD患者。

关键数值与推荐

  • 国际指南推荐慢性肝病患者接种两剂暴露前甲型肝炎疫苗以预防严重并发症。

临床怎么用

  • 作者认为英格兰慢性肝病成人甲肝疫苗接种率低且存在年龄、城乡和社会经济状态差异,应采取步骤减少疫苗接种中的不平等。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: International guidelines recommend the administration of two doses of pre-exposure hepatitis A vaccination for people with chronic liver disease to prevent severe complications. We aimed to describe hepatitis A vaccination coverage and mortality in adults with chronic liver disease in England. METHODS: We did a retrospective cohort study using routinely collected medical record data from the Oxford-Royal College of General Practitioners Research and Surveillance Centre (RSC) primary care sentinel network. We included people aged 18 years or older who were diagnosed with chronic liver disease between Jan 1, 2012, and Dec 31, 2022. The primary outcome of interest was hepatitis A vaccination. Hepatitis A vaccination coverage was calculated using the number of vaccinated people with chronic liver disease as the numerator and the chronic liver disease population in the RSC dataset as the denominator. We compared individual characteristics by vaccination status using descriptive statistics. We used a multistate survival model to estimate the transition probabilities between four states: (1) diagnosis of chronic liver disease; (2) first hepatitis A vaccination; (3) second hepatitis A vaccination; and (4) death. FINDINGS: 664 571 individuals aged 18 years or older with chronic liver disease were identified from the RSC sentinel network population, of whom 625 079 individuals were included in our analysis. Of 625 079 individuals with chronic liver disease, 13 875 (2·2%) had received a first hepatitis A vaccination, 3007 (0·4%) had received a second dose, 732 (5·3%) of 13 875 vaccinated individuals died, and 101 065 (16·5%) of 611 204 individuals without vaccination died during the study period. Adjusting for death as a competing risk, vaccination was more likely among younger age quintiles (hazard ratio 5·46 [95% CI 5·13-5·81]), non-smokers (1·59 [1·54-1·65]), residents of urban areas (1·28 [1·21-1·35]), individuals with higher socioeconomic status (1·06 [1·03-1·10]), and individuals with a diagnosis of metabolic dysfunction-associated steatotic liver disease (MASLD; 1·71 [1·64-1·78]). Individuals with a history of harmful alcohol use (0·36 [0·32-0·39]), type 1 diabetes (0·46 [0·36-0·57]), chronic kidney disease (0·63 [0·57-0·70]), or mental disorders (0·66 [0·64-0·69]) were less likely to be vaccinated. The lowest risk of mortality was in people with chronic liver disease of infectious or autoimmune aetiology and in people with MASLD. INTERPRETATION: Hepatitis A vaccine uptake among people with chronic liver disease in England is low, with disparities by age, location (urban vs rural), and socioeconomic status. Steps should be taken to reduce the inequalities in vaccine administration. FUNDING: GlaxoSmithKline's Investigator Sponsored Studies Program.

来源:Lancet Public Health,查看原文。版权归原作者所有。

引用

  1. Meza-Torres B, Jamie G, Wimalaratna R, et al. Hepatitis A vaccination coverage in adults with chronic liver disease in primary care in England: a retrospective cohort study. Lancet Public Health. 2025. PMID: 40738551. doi:10.1016/S2468-2667(25)00139-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。